AlphaFold for Drug Discovery

AlphaFold for Drug Discovery stands as the most impactful AI application in healthcare, with Google DeepMind's protein structure database expanding to 200 million proteins by 2023 and updating to predict molecular interactions in 2024. This tool has become foundational for pharmaceutical R&D, integrated by Pfizer, Novartis, AstraZeneca, and 190 other pharma companies into their pipelines. Researchers credit AlphaFold for identifying over 20 novel drug targets that would have required years to discover via traditional crystallography, accelerating the timeline by an average of 6 months per target. It outperforms #2 AI Radiology in sheer scale of molecular discovery, offering a data-driven approach that has already entered clinical trials for 5 new compounds targeting antibiotic resistance.